Accutane - Product Information
|Class:||Miscellaneous antineoplastics, Miscellaneous uncategorized agents|
|Ingredients:||Isotretinoin, beeswax, black iron oxide, gelatin, glycerol, hydrogenatedhydrolysed starch, hydrogenated soybean oil, mannitol,partially hydrogenated soybean oil, propylene glycol, rediron oxide, shellac, sorbitol, soybean oil, titaniumdioxide|
Summary Product Information
|Dosage Form ⁄
|Clinically Relevant Non–medicinal
|Soybean Oil (see CONTRAINDICATIONS)|
|Oral||Capsules ⁄40 mg||Glycerol|
|Methylparaben (see CONTRAINDICATIONS)|
|Propylparaben (see CONTRAINDICATIONS)|
|Soybean Oil (see CONTRAINDICATIONS)|
|Sunset Yellow FCF|
|For a complete listing of non–medicinal ingredients see Dosage Forms, Composition and Packaging section.|
Indications and Clinical Use
ACCUTANE ROCHE (isotretinoin) is indicated for the treatment of:
- Severe Nodular and/or Inflammatory Acne
- Acne Conglobata
- Recalcitrant Acne
Because of significant side effects associated with its use, ACCUTANE should be reserved for patients where the conditions listed above are unresponsive to conventional first line therapies.
ACCUTANE should only be prescribed by physicians knowledgeable in the use of retinoids systemically, who understand the risk of teratogenicity in females of child bearing age and who are experienced in counselling young adults for whom ACCUTANE is generally indicated (see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS: Serious Warnings and Precautions and Special Populations, Pregnant Women).
A careful assessment of the patient’s mental state should be made, including whether or not they have a history of previous psychiatric illness (see WARNINGS AND PRECAUTIONS, Serious Warnings and Precautions, Psychiatric).
It is strongly recommended that each ACCUTANE prescription be limited to a one-month supply in order to encourage patients to return for follow-up to monitor side-effects. Prescriptions of ACCUTANE for women of child-bearing potential should be limited to 30 days of treatment and continuation of treatment requires a new prescription.
The use of ACCUTANE in pediatric patients less than 12 years of age is not recommended. The use of ACCUTANE for the treatment of severe recalcitrant nodular acne in pediatric patients ages 12 to 17 years should be given careful consideration, especially for those patients where a known metabolic or structural bone disease exists (see WARNINGS AND PRECAUTIONS: Special Populations, Pediatrics).
Clinical studies of ACCUTANE did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. Although reported clinical experience has not identified differences in responses between elderly and younger patients, effects of aging might be expected to increase some risks associated with isotretinoin therapy
Accutane (Isotretinoin) is Contraindicated in Pregnancy.
Females must not become pregnant while taking ACCUTANE or for at least one month after its discontinuation. ACCUTANE causes severe birth defects in a very high percentage of infants born to women who became pregnant during treatment with ACCUTANE in any amount, even for a short period of time. Birth defects which have been documented following ACCUTANE exposure include: CNS (hydrocephalus, hydranecephaly, microcephaly, posterior fossa abnormalities, cranial nerve dysfunction, cerebellar malformation); craniofacial (anotia, microtia, low set ears, small or absent external auditory canals, microphthalmia, facial dysmorphia, cleft palate); cardiac (septal defects, aortic arch abnormalities, tetralogy of Fallot); thymus gland abnormalities; and parathyroid hormone deficiency. Cases of IQ scores less than 85 with or without other abnormalities have been reported.
- Potentially any exposed fetus can be affected. There are no accurate means of determining whether an exposed fetus has been affected (see WARNINGS AND PRECAUTIONS: Special populations, Pregnant women).
- If pregnancy does occur during treatment with ACCUTANE or for one month after its discontinuation, ACCUTANE treatment must be immediately stopped and the physician and patient should discuss the desirability of continuing the pregnancy.
ACCUTANE should only be prescribed by physicians knowledgeable in the use of retinoids systemically (see INDICATIONS AND CLINICAL USE).
ACCUTANE is also contraindicated in the following conditions:
- breastfeeding women,
- hepatic and renal insufficiency, hypervitaminosis A,
- patients with excessively elevated blood lipid values,
- patients taking tetracyclines (see WARNINGS AND PRECAUTIONS, Serious Warnings and Precautions, Neurologic and DRUG INTERACTION: Drug-Drug Interactions).
- patients who are sensitive to isotretinoin, or to any of the excipients. ACCUTANE capsules contain hydrogenated soybean oil, parabens, partially hydrogenated soybean oil, and soybean oil (see DOSAGE FORMS, COMPOSITION AND PACKAGING: Composition).
Warnings and Precautions
Serious Warnings and Precautions
All patients must sign the informed consent form prior to initiating therapy.
ACCUTANE (isotretinoin) is a known teratogen contraindicated in pregnancy (see boxed CONTRAINDICATIONS). Physicians should only prescribe ACCUTANE to females of childbearing potential if ALL the conditions described below under “Conditions of use” are met.
In addition, when prescribing this drug to female patients of childbearing potential, physicians must use Hoffmann-La Roche Limited’s PREGNANCY PREVENTION PROGRAM®, which includes comprehensive information about the potential risks of this drug, a checklist for criteria which must be met prior to prescribing this drug to female patients of childbearing potential, detailed information on birth control options, a patient informed consent for review and signature, and monthly pregnancy reminders for physicians to use at each patient visit during the treatment period.
Some patients treated with ACCUTANE have become depressed and some attempted or committed suicide. Although a causal relationship has not been established, all patients should be screened and monitored for signs of depression before and during therapy (see WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests). Physicians should determine whether the patient may be depressed or has a history of depression including a family history of major depression before starting therapy with ACCUTANE. If symptoms of depression develop or worsen during treatment with ACCUTANE, the drug should be discontinued promptly and the patient referred for appropriate psychiatric treatment as necessary. However, discontinuation of ACCUTANE may not alleviate symptoms and therefore further psychiatric or psychological evaluation may be necessary.
A Psychiatric Assessment Checklist is available to assist physicians in screening patients for depression/suicidality prior to treatment and in monitoring for the development of psychiatric symptoms during treatment. This checklist is provided to the physician viathe www.acneandu.ca website or by contacting the Roche Drug Information line at 1-888-762-4388.
ACCUTANE use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines (see CONTRAINDICATIONS and DRUG INTERACTIONS: Drug-Drug Interactions). Early symptoms of pseudotumor cerebri include headache, nausea and vomiting, and visual disturbances. Patients with these symptoms should be screened for papilledema and, if present, the drug should be discontinued immediately and the patient referred to a neurologist for diagnosis and care. Concomitant treatment with tetracyclines should be avoided (see CONTRAINDICATIONS and DRUG INTERACTIONS: Drug-Drug Interactions).
Serious Skin Reactions
There have been very rare post-marketing reports of severe skin reactions (e.g., erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN)) associated with ACCUTANE use. These events may be serious and result in hospitalization, life threatening events, disfiguration, disability and/or death. ACCUTANE treatment should be discontinued if the patient develops any of the following reactions: rash, especially if associated with fever and/or malaise, conjunctivitis (red or inflamed eyes); blisters on legs, arms or face and/or sores in mouth, throat, nose or eyes; peeling skin or other serious skin reactions.
Conditions of Use
- The patient has severe disfiguring nodular and/or inflammatory acne, acne conglobata or recalcitrant acne that has not responded to standard therapy, including systemic antibiotics.
- The patient is reliable in understanding and carrying out instructions.
- All patients must sign the informed consent form prior to initiating therapy. This formis provided to the physician via the www.acneandu.ca website or by contacting the Roche Drug Information line at 1-888-762-4388.
- The patient is able and willing to comply with the mandatory effective contraceptive measures.
- The patient has received, and acknowledged understanding of, a careful oral and printed explanation of the hazards of fetal exposure to ACCUTANE and the risk of possible contraception failure. This explanation may include showing a line drawing to the patient of an infant with the characteristic external deformities resulting from ACCUTANE exposure during pregnancy.
- The patient has been informed and understands the need to rapidly consult her physician if there is a risk of pregnancy.
- The patient understands the need for rigorous follow-up on a monthly basis.
- The patient uses effective contraception without any interruption for one month before beginning ACCUTANE therapy, during ACCUTANE therapy and for one month following discontinuation of ACCUTANE therapy. It is recommended that two reliable forms of contraception be used simultaneously (see WARNINGS AND PRECAUTIONS: Special Populations, Pregnant Women).
- The patient has had two negative pregnancy tests before starting ACCUTANE therapy with the first pregnancy test conducted at initial assessment when the patient is qualified for ACCUTANE therapy by the physician. The patient has had a second serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL with a negative result, performed in a licensed laboratory, within 11 days prior to initiating therapy. The patient has had two or three days of the next normal menstrual period before ACCUTANE therapy is initiated.
- In the event of relapse treatment, the patient must also use the same uninterrupted and effective contraceptive measures one month prior to, during and for one month after ACCUTANE.
ACCUTANE is contraindicated in females of childbearing potential unless ALL of the following conditions apply:
(Re items 4 to 10 see WARNINGS AND PRECAUTIONS: Special Populations, Pregnant Women).
Even female patients who normally do not employ contraception due to a history of infertility, or claim absence of sexual activity should be advised to employ contraception while taking ACCUTANE, following the above guidelines. Even female patients who have amenorrhea must follow all the advice on effective contraception unless the patient has undergone hysterectomy, bilateral oophorectomy, or has been medically confirmed to be postmenopausal.
Information concerning the PREGNANCY PREVENTION PROGRAM (see boxed Serious Warnings and Precautions) has also been provided directly to patients via the ACCUTANE compliance packaging. This “Patient Information” asks female patients of childbearing potential, who have not been counselled using Hoffmann-La Roche PREGNANCY PREVENTION PROGRAM, to contact their physician for further information. All patient
materials and physician materials can be downloaded from the www.acneandu.ca website or by contacting the Roche Drug Information line at 1-888-762-4388.
Patients should also be informed that confidential contraception counselling (provided by a health care professional) is available from Hoffmann-La Roche Limited.
There is an extremely high risk (25% or greater) that major human fetal abnormalities will occur if pregnancy occurs during treatment with ACCUTANE or up to one month following its discontinuation. Potentially any exposed fetus can be affected. These abnormalities, associated with ACCUTANE administration during pregnancy, have been reported and include:
CNS (hydrocephalus, hydranecephaly, microcephaly, posterior fossa abnormalities, cranial nerve dysfunction, cerebellar malformation); craniofacial (anotia, microtia, low set ears, small or absent external auditory canals, microphthalmia, facial dysmorphia, cleft palate); cardiac (septal defects, aortic arch abnormalities, tetralogy of Fallot); thymus gland abnormalities; and parathyroid hormone deficiency. Cases of IQ scores less than 85 with or without other abnormalities have been reported.
Female patients of childbearing potential must not be given ACCUTANE until pregnancy is excluded. The patient must have two negative pregnancy tests before starting ACCUTANE therapy with the first pregnancy test conducted at initial assessment when the patient is qualified for ACCUTANE therapy by the physician. A second pregnancy test must be performed within 11 days prior to starting ACCUTANE treatment. ACCUTANE treatment should start on the second or third day of the next normal menstrual period following this negative pregnancy test.
It is mandatory that all female patients of childbearing potential treated with ACCUTANE have regular monthly pregnancy tests during treatment and one month after the discontinuation of treatment. The dates and results of pregnancy tests should be documented. The blood monitoring chart can be used to document these results as well as to serve as a reminder of all the tests that should be carried out and their frequency. This physicianmaterial can be downloaded from the www.acneandu.ca website or by contacting the Roche Drug Information line at 1-888-762-4388.
These pregnancy tests will:
- Serve primarily to reinforce to the patient the necessity of avoiding pregnancy.
- In the event of accidental pregnancy, provide the physician and patient an immediate opportunity to discuss the serious risk to the fetus from this exposure to ACCUTANE and the desirability of continuing the pregnancy in view of the potential teratogenic effect of ACCUTANE (see CONTRAINDICATIONS and TOXICOLOGY: Reproduction and Teratology Studies).
Effective contraception must be used for at least one month before starting ACCUTANE treatment, during treatment and for at least one month following the discontinuation of ACCUTANE treatment. Any birth control method can fail. Therefore itis recommended that two reliable forms of contraception be used simultaneously (see DRUG INTERACTIONS: Drug-Drug Interactions). At least 1 of these forms of contraception must be a primary form, unless the patient has undergone a hysterectomy, bilateral oophorectomy, or has been medically confirmed to be postmenopausal. Effective forms of contraception include: primary forms which are tubal ligation, partner's vasectomy, intrauterine devices, birth control pills, and topical/injectable/insertable hormonal birth control products and secondary, or barrier forms of contraception which include diaphragms, latex condoms, and cervical caps. A diaphragm and cervical cap must each be used with a spermicide.
Pregnancy occurring during treatment with ACCUTANE and for one month after its discontinuation carries the risk of fetal malformation and the increased risk of spontaneous abortion (see CONTRAINDICATIONS and TOXICOLOGY: Reproduction and Teratology Studies). ACCUTANE, treatment must be stopped and the patient should be fully counselled on the serious risk to the fetus should they become pregnant while undergoing treatment. If pregnancy does occur during this time the physician and patient should discuss the desirability of continuing the pregnancy.
It is not known whether isotretinoin is excreted in human milk. As isotretinoin is highly lipophilic, the passage of the drug in human milk is very likely. Because of the potential for adverse effects, women should not breast-feed if they are receiving ACCUTANE (see CONTRAINDICATIONS).
The long term safety of ACCUTANE, in prepubertal children (< 12 years of age), has not been established.
In studies with ACCUTANE, adverse reactions reported in pediatric patients ages 12 to 17 years were similar to those described in adults except for the increased incidence of back pain and arthralgia (both of which were sometimes severe) and myalgia in pediatric patients (see ADVERSE REACTIONS).
Pediatric patients and their caregivers should be informed that approximately 29% (104/358) of pediatric patients treated with ACCUTANE developed back pain. Back pain was severe in 13.5% (14/104) of the cases and occurred at a higher frequency in female patients than male patients. Arthralgias were experienced in 22% (79/358) of pediatric patients. Arthralgias were severe in 7.6% (6/79) of patients. Appropriate evaluation of the musculoskeletal system should be done in patients who present with these symptoms during or after a course of ACCUTANE. Consideration should be given to discontinuation of ACCUTANE if any significant abnormality is found.
Geriatrics (>65 Years of Age)
Clinical studies of isotretinoin did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects.
Special Patient Groups
In high risk patients (with diabetes, obesity, alcoholism or lipid metabolism disorder) undergoing treatment with ACCUTANE, more frequent checks of serum values for lipids (see WARNINGS AND PRECAUTIONS: Endocrine and Metabolism and Hepatic/Biliary/Pancreatic) and/or blood glucose may be necessary.
The available data suggest that the level of maternal exposure from the semen of the patients receiving ACCUTANE is not of a sufficient magnitude to be associated with the teratogenic effects of ACCUTANE. The threshold dose of isotretinoin exposure causing birth defects is not known. Postmarketing reports through 20 years include 4 with isolated defects compatible with features of retinoid exposed fetus; however 2 of these reports were incomplete, and 2 had other possible explanations for the defects observed.
Male patients should be reminded that they must not share their medication with anyone, particularly not females.
Isotretinoin, in therapeutic dosages, does not affect the number, motility and morphology of sperm.
Both male and female patients should be given a copy of the Consumer Information (Part III).
It is recommended that blood donation for transfusion purposes be deferred during therapy with ACCUTANE and for one month after discontinuation of treatment. Theoretically, blood from such donors could present a small risk to the fetus if transfused to a pregnant mother during the first trimester of pregnancy.
Approximately 25% of patients receiving ACCUTANE experienced an elevation in plasma triglycerides. Approximately 15% developed a decrease in high density lipoproteins and about 7% showed an increase in cholesterol levels. These effects on triglycerides, HDL and cholesterol were reversible upon reduction of the dose or cessation of ACCUTANE therapy (see ADVERSE REACTIONS: Laboratory Abnormalities).
Patients with increased tendency to develop hypertriglyceridemia include those with diabetes mellitus, obesity, increased alcohol intake and familial history.
The cardiovascular consequences of hypertriglyceridemia are not well understood, but may increase the patient’s risk status. Therefore, every attempt should be made to control significant triglyceride elevation (see WARNINGS AND PRECAUTIONS: Monitoring and Laboratory Tests). Some patients have been able to reverse triglyceride elevation by reduction in weight, restriction of dietary fat and alcohol, and reduction in dose while continuing ACCUTANE. An obese male patient with Darier’s disease developed elevated triglycerides and subsequent eruptive xanthomas.
Impaired hearing at certain frequencies has been reported in some patients treated with ACCUTANE. Patients who experience tinnitus or hearing impairment should discontinue ACCUTANE treatment and be referred for specialized care for further evaluation.
Endocrine and Metabolism
Patients with diabetes or a family history of diabetes may experience problems with the control of their blood sugar during ACCUTANE therapy. Therefore, known or suspected diabetics should have periodic blood sugar determinations. Although no causal relationship has been established, elevated fasting blood sugars have been reported, and new cases of diabetes have been diagnosed during ACCUTANE therapy (see ADVERSE REACTIONS: Clinical Trial and Post-Market Adverse Reactions, Laboratory Abnormalities).
ACCUTANE has been temporally associated with inflammatory bowel disease (including regional ileitis, colitis and hemorrhage) in patients without a prior history of intestinal disorders. Patients experiencing abdominal pain, rectal bleeding or severe diarrhea should discontinue ACCUTANE immediately.
Liver function tests should be monitored before treatment and at regular intervals during treatment (one month after the start of treatment and at least three month intervals thereafter) unless more frequent monitoring is clinically indicated. Several cases of clinical hepatitis have been noted which are considered to be possibly or probably related to ACCUTANE therapy. Additionally, mild to moderate elevations of liver enzymes have been observed in approximately 15% of individuals treated during clinical trials, some of which normalized with dosage reduction or continued administration of the drug. If normalization does not readily occur, or if hepatitis is suspected during treatment with ACCUTANE, the drug should be discontinued and the etiology further investigated (see WARNINGS AND PRECAUTIONS: Monitoring and Laboratory Tests).
There have been some reports of acute pancreatitis, which is known to be potentially fatal. This is sometimes associated with elevation of serum triglycerides in excess of 800 mg/dL or 9 mmol/L (see ADVERSE REACTIONS: Clinical Trial and Post-Market Adverse Drug Reactions, Laboratory Abnormalities). Therefore, every attempt should be made to control significant triglyceride elevation (see WARNINGS AND PRECAUTIONS: Cardiovascular). ACCUTANE should be discontinued if uncontrolled hypertriglyceridemia or symptoms of pancreatitis occur.
Anaphylactic reactions have been reported. These reactions were more serious after prior exposure to topical retinoids. Allergic cutaneous reactions and serious cases of allergic vasculitis, often with purpura (bruises and red patches) of the extremities and extracutaneous involvement have been reported. Severe allergic reactions necessitate interruption of therapy and careful monitoring.
Effects of multiple courses of ACCUTANE on the developing musculoskeletal system are unknown. There is some evidence that long- term, high-dose, or multiple courses of therapy with isotretinoin have more of an effect than a single course of therapy on the musculoskeletal system (see also WARNINGS AND PRECAUTIONS: Special Populations, Pediatrics).
In an open-label clinical trial (N=217) of a single course of therapy with ACCUTANE for severe recalcitrant nodular acne in pediatric patients 12 to 17 years, bone density measurements at several skeletal sites were not significantly decreased (lumbar spine change >-4% and total hip change>-5%) or were increased in the majority of patients. One patient had a decrease in lumbar spine bone mineral density >4% based on unadjusted data. Sixteen (7.9%) patients had decreases in lumbar spine bone mineral density >4%, and all the other patients (92%) did not have significant decreases or had increases (adjusted for body mass index). Nine patients (4.5%) had a decrease in total hip bone mineral density >5% based on unadjusted data. Twenty-one (10.6%) patients had decreases in total hip bone mineral density >5%, and all the other patients (89%) did not have significant decreases or had increases (adjusted for body mass index). Follow-up studies performed in 8 of the patients with decreased bone mineral density for up to 11 months thereafter demonstrated increasing bone density in 5 patients at the lumber spine, while the other 3 patients had lumbar spine bone density measurements below baseline values. Total hip bone mineral densities remained below baseline (range-1.6% to -7.6%) in 5 of 8 patients (62.5%).
In this clinical trial transient elevations in CPK were observed in 12% of patients, including those undergoing strenuous physical activity in association with reported musculoskeletal adverse events such as back pain, arthralgia, limb injury, or muscle sprain. In these patients, approximately half of the CPK elevations returned to normal within 2 weeks and half returned to normal within 4 weeks. No cases of rhabdomyolysis were reported in this trial.
In a separate open-label extension study of 10 patients, ages 13-18 years, who started a second course of ACCUTANE 4 months after the first course, two patients showed a decrease in mean lumbar spine bone mineral density up to 3.25%.
Spontaneous reports of osteoporosis, osteopenia, bone fractures, and delayed healing of bone fractures have been seen in the ACCUTANE population. While causality to ACCUTANE has not been established, an effect cannot be ruled out. Longer term effects have not been studied. It is important that ACCUTANE be given at the recommended doses for no longer than the recommended duration.
Although an effect of ACCUTANE on bone loss is not established, physicians should use caution when prescribing ACCUTANE to patients with a genetic predisposition for age-related osteoporosis, a history of childhood osteoporosis conditions, osteomalacia, or other disorders of bone metabolism. This would include patients diagnosed with anorexia nervosa and those who are on chronic drug therapy that causes drug-induced osteoporosis/osteomalacia and/or affects vitamin D metabolism, such as systemic corticosteroids and any anticonvulsant. Patients may be at increased risk when participating in sports with repetitive impact where the risks of spondylolisthesis with and without pars fractures and hip growth plate injuries in early and late adolescence are known. There are spontaneous reports of fractures and/or delayed healing in patients while on treatment with ACCUTANE or following cessation of treatment with ACCUTANE while involved in these activities. While causality to ACCUTANE has not been established, an effect cannot be ruled out.
Due to possible occurrence of bone changes, a careful evaluation of the risk/benefit ratio should be carried out in every patient and ACCUTANE administration should be restricted to severe cases of acne. Bone changes including, premature epiphyseal closure, hyperostosis and calcification of tendons and ligaments have occurred after several years of administration at high doses for treating disorders of keratinization. The dose levels, duration of treatment and total cumulative dose in these patients generally far exceeded those recommended for the treatment of acne.
In clinical trials of disorders of keratinization, with a mean dose of 2.24 mg/kg/day, a high prevalence of skeletal hyperostosis was noted. Two children showed x- ray findings suggestive of premature closure of the epiphysis. Additionally, skeletal hyperostosis was noted in six of eight patients in a prospective study of disorders of keratinization.
Minimal skeletal hyperostosis and calcification of tendons have also been observed by x-rays in prospective studies of cystic acne patients treated with a single course of therapy at recommended doses. There are spontaneous reports of premature epiphyseal closure in acne patients receiving recommended doses of ACCUTANE. The effect of multiple courses of ACCUTANE on epiphyseal closure is unknown.
In a clinical study of 217 pediatric patients (12 to 17 years) with severe recalcitrant nodular acne, hyperostosis was not observed after 16 to 20 weeks of treatment with approximately 1 mg/kg/day of ACCUTANE given in two divided doses. Hyperostosis may require a longer time frame to appear. The clinical course and significance remain unknown.
Myalgia and arthralgia (mild to moderate) may occur and may be associated with reduced tolerance to vigorous exercise (see ADVERSE REACTIONS: Clinical Trial and Post-Market Adverse Drug Reactions, Musculoskeletal). Instances of raised serum creatine phosphokinase (CPK) values have been reported in patients receiving ACCUTANE, particularly those undertaking vigorous physical activity. Discontinuation of ACCUTANE may be required.
Corneal opacities have occurred in patients receiving ACCUTANE for acne and more frequently when higher drug dosages were used in patients with disorders of keratinization. Dry eyes, corneal opacities, decreased night vision, keratitis, blepharitis and conjunctivitis usually resolve after discontinuation of therapy. Due to the possible occurrence of keratitis, patients with dry eyes should be monitored. All ACCUTANE patients experiencing visual difficulties should discontinue the drug and have an ophthalmological examination. (see ADVERSE REACTIONS: Clinical Trial and Post-Market Adverse Drug Reactions, Ophthalmologic). Dry eyes, can be helped by the application of a lubricating eye ointment or by the application of tear replacement therapy. Intolerance to contact lenses may occur which may necessitate the patient to wear glasses during treatment.
A number of cases of decreased night vision have occurred during ACCUTANE therapy and in rare instances have persisted after therapy (see ADVERSE REACTIONS: Clinical Trial and Post-Market Adverse Drug Reactions, Ophthalmologic). Because the onset in some patients was sudden, patients should be advised of this potential problem and warned to be cautious when driving or operating any vehicle at night. ACCUTANE patients experiencing visual impairment should discontinue treatment and have an ophthalmological examination.
Visual problems should be carefully monitored.
Acute exacerbation of acne is occasionally seen during the initial period but this subsides with continued treatment, usually 7-10 days, and usually does not require dose adjustment.
Exposure to intense sunlight or to UV rays should be avoided. When necessary a sun-protection product with a high protection factor of a least SPF 15 should be used.
It is recommended that aggressive chemical dermabrasion and cutaneous laser treatment be avoided in patients on ACCUTANE and for a period of 5-6 months after the end of treatment because of the risk of hypertrophic scarring in atypical areas, and more rarely hyper- or hypo-pigmentation in treated areas.
It is recommended that wax epilation be avoided in patients on ACCUTANE therapy and for a period of 5-6 months after treatment because of the risk of epidermal stripping, scarring or dermatitis.
Concurrent administration of ACCUTANE with keratolytic or exfoliative anti-acne agents should be avoided as local irritation may increase.
Patients should be advised to use a skin- moisturizing ointment or cream and a lip balm from the start of treatment as ACCUTANE is likely to cause dryness of the skin and lips.
There have been post-marketing reports of severe skin reactions. (see WARNINGS AND PRECAUTIONS: Serious Skin Reactions)
Monitoring and Laboratory Tests
The patient should have two negative pregnancy tests (β-hCG in urine or serum) before starting ACCUTANE therapy with the first pregnancy test conducted at initial assessment when the patient is qualified for ACCUTANE therapy by the physician. The patient then should have a second pregnancy test with a sensitivity of at least 25 mIU/mL with a negative result, performed in a licensed laboratory, within 11 days prior to initiating therapy. The patient has had two or three days of the next normal menstrual period before ACCUTANE therapy is initiated. Pregnancy test must be repeated monthly forpregnancy detection during ACCUTANE treatment and at one month after discontinuation of treatment. The dates and results of the pregnancy tests should be documented.
Signs of Depression
sad mood, hopelessness, feeling of guilt, worthlessness or helplessness, loss of pleasure or interest in activities, fatigue, difficulty concentrating, changes in sleep pattern, change in weight or appetite, suicidal thoughts or attempts, restlessness, irritability, acting on dangerous impulses, and persistent physical symptoms unresponsive to treatment. If symptoms of depression develop or worsen during treatment with ACCUTANE, the drug should be discontinued promptly and the patient referred for appropriate psychiatric treatment.
The following tests are required before starting ACCUTANE, at first month, then as clinically indicated:
- Serum blood lipid determinations (under fasting conditions) should be performed before ACCUTANE is given and then at intervals (one month after the start of therapy) until the lipid response to ACCUTANE is established (which usually occurs within four weeks), and also at the end of treatment.
- Complete blood count and differential: for early detection of leukopenia, neutropenia, thrombocytopenia and anemia.
- Liver function tests: Increases in about 15% of ALT, AST, ALP baseline levels have been reported. Liver function tests should be monitored before treatment and at regular intervals during treatment (one month after the start of treatment and at least three month intervals thereafter) unless more frequent monitoring is clinically indicated.
- Blood glucose levels: all patients and in particular patients with known or suspected diabetes should have periodic blood sugar determinations.
Adverse Drug Reaction Overview
The adverse reactions listed below reflect the experience from clinical studies of ACCUTANE (isotretinoin), and the post-marketing experience. The relationship of some of these events to ACCUTANE therapy is unknown.
Many of the side effects and adverse reactions seen or expected in patients receiving ACCUTANE are similar to those described in patients taking high doses of vitamin A.
Clinical Trial and Post-Market Adverse Drug Reactions
Dose-Relationship and Duration
Cheilitis and hypertriglyceridemia are usually dose related.
Adverse reactions were generally reversible when therapy was discontinued; however, some have persisted after cessation of therapy.
The most common side-effects are mucocutaneous or dermatologic. The common side effects include: cheilitis (96%), facial erythema/dermatitis (55%), dry nose (51%), desquamation (50%), pruritus (30%), dry skin (22%), conjunctivitis (19%), alopecia (13%), irritation of the eyes (11%), rash (<10%). Dryness of the nasal mucosa and pharynx may be associated with mild epistaxis and hoarseness, respectively. Mild-to -moderate conjunctivitis may be alleviated by use of an ophthalmic ointment. In rare cases, hair loss persisted after treatment was completed.
Approximately 13% of patients experience joint pain during treatment.
Peeling of palms and soles, skin infections, increased susceptibility to sunburn, non-specific urogenital symptoms, non-specific gastrointestinal symptoms, headache, fatigue occurred in approximately 5% of patients.
Body as a whole: weight loss, anemia, lymphadenopathy, vasculitis including Wegener’s granulomatosis, allergic vasculitis, allergic responses, and systemic hypersensitivity.
Cardiovascular: edema, transient pain in the chest, palpitations, tachycardia, vascular thrombotic disease, stroke
Endocrine and Metabolism: new cases of diabetes (see WARNING AND PRECAUTIONS: Endocrine and Metabolism)
Gastrointestinal: nausea, severe diarrhea, mild gastrointestinal bleeding, rectal bleeding, abdominal pain, inflammatory bowel disease (including regional ileitis, colitis and hemorrhage) (see WARNINGS AND PRECAUTIONS: Gastrointestinal)
Hearing Disorders: tinnitus, impaired hearing at certain frequencies.
Hepatic/Biliary/Pancreatic: Patients treated with ACCUTANE especially those with high triglyceride levels are at risk of developing pancreatitis. Rare cases of fatal pancreatitis and several cases of clinical hepatitis have been reported (see WARNINGS AND PRECAUTIONS: Hepatic/Biliary/Pancreatic).
Mucocutaneous and Dermatologic: flushing, changes in skin pigment, urticaria, bruising, disseminated herpes simplex, hair problems (other than thinning), hirsutism, erythema nodosum, paronychia, nail dystrophy, pyogenic granuloma, bleeding and inflammation of the gums, acne fulminans, exanthema, sweating, increased formation of granulation tissue, photoallergic/photosensitizing reactions, skin fragility. Acne flare occurs at the start of treatment and persists for several weeks.
During the post-marketing period, erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) have been reported to be associated with ACCUTANE (see WARNING AND PRECAUTIONS: Serious Skin Reactions).
Musculoskeletal: arthritis, muscle pain (myalgia; elevations of serum CPK values), arthralgia, calcification of ligaments, tendon and tendinitis, reduced bone density, back pain, premature fusion of epiphyses, hyperostosis (see WARNINGS AND PRECAUTIONS: Musculoskeletal, Hyperostosis).
There have been postmarketing serious reports of rhabdomyolysis, often leading to hospitalization and some with fatal outcome, particularly in those undergoing strenuous physical activity.
Neurologic: seizures, dizziness, nervousness, drowsiness, malaise, weakness, insomnia, lethargy, paresthesia, benign intracranial hypertension (see WARNINGS AND PRECAUTIONS: Serious Warnings and Precautions, Neurologic)
Ophthalmologic: optic neuritis, photophobia, eye lid inflammation, lenticular cataracts, keratitis, blurred vision, blepharitis, conjunctivitis, decreased night vision, papilledema as sign of benign intracranial hypertension and colour vision disturbances. Dry eyes and/or decreased tolerance to contact lenses have also been reported during therapy. In some instances these conditions have persisted after cessation of therapy.
Of 72 patients who had normal pre-treatment ophthalmological examinations, five developed corneal opacities while taking ACCUTANE (all five patients had a disorder of keratinization). Corneal opacities have also been reported in nodular and/or inflammatory acne patients treated with ACCUTANE (see WARNINGS AND PRECAUTIONS: Ophthalmologic). Decrease in night vision has been reported and in rare instances has persisted (see WARNINGS AND PRECAUTIONS: Ophthalmologic). Cataracts and visual disturbances have also been reported.
Psychiatric Disorders: Depression, psychotic symptoms and, rarely, suicide attempts, suicide, and aggressive and/or violent behaviours (see WARNINGS AND PRECAUTIONS: Psychiatric). Depression has been reported during and after therapy. In some of these patients, depression has subsided with discontinuation of therapy and recurred when ACCUTANE therapy was reintroduced. Emotional instability has been reported with ACCUTANE.
Respiratory: respiratory infections
Bronchospasm has been rarely reported; sometimes in patients with pre-history of asthma.
Reproductive system: abnormal menses.
Urinary system: glomerulonephritis
Laboratory Abnormalities: ACCUTANE therapy induces changes in serum lipids in a significant number of treated subjects. These changes consisted of: elevation of serum triglycerides (25% of patients), mild to moderate decrease in serum high density lipoprotein (HDL) (16% of patients), and minimal elevations of serum cholesterol (7% of patients) . Abnormalities of serum triglycerides, HDL and cholesterol were reversible upon cessation of ACCUTANE therapy.
A rise in serum levels of liver enzymes may occur, especially with higher dosages. Although the changes have usually been within the normal range, and may return to baseline levels despite continued treatment, significant increases have occurred in a few cases, necessitating dosage reduction or discontinuation of ACCUTANE (see WARNINGS AND PRECAUTIONS: Hepatic/Biliary/Pancreatic). An elevated erythrocyte sedimentation rate may also occur (40% of patients).
Other less commonly reported laboratory abnormalities were: Elevated fasting blood sugar, elevated CPK, and hyperuricemia. Decreases in red blood cell parameters, decreases in white blood cell counts, elevated sedimentation rates, elevated platelet counts, thrombocytopenia and anemia. White blood cells in the urine, proteinuria, and red blood cells in the urine.
Rare cases of benign intracranial hypertension ‘pseudotumor cerebri’ have been reported after use of ACCUTANE (isotretinoin) and/or tetracyclines. Therefore, concomitant treatment with tetracyclines must be avoided (see WARNINGS AND PRECAUTIONS: Serious Warnings and Precautions, Neurologic).
Because of the relationship of ACCUTANE to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A, to avoid additive toxic effects.
ACCUTANE has not been shown to alter the pharmacokinetics of phenytoin in a study in seven healthy volunteers. These results are consistent with the in vitro finding that neither isotretinoin nor its metabolites induce or inhibit the activity of the CYP 2C9 human hepatic P450 enzyme. Phenytoin is known to cause osteomalacia. No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between phenytoin and ACCUTANE. Therefore, caution should be exercised when using these drugs together.
In a study of 31 premenopausal women with severe recalcitrant nodular acne receiving OrthoNovum 7/7/7 1Tablets as an oral contraceptive agent, ACCUTANE at the recommended dose of 1 mg/kg/day, did not induce clinically relevant changes in the pharmacokinetics of ethinyl estradiol and norethindrone and in the serum levels of progesterone, follicle-stimulating hormone (FSH) and luteinizing hormone (LH). A drug interaction that decreases effectiveness of hormonal contraceptives has not been entirely ruled out for ACCUTANE.
Microdosed progesterone preparations (minipills)
Are not a suitable method of contraception during ACCUTANE therapy.
Systemic corticosteroids are known to cause osteoporosis. No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between systemic corticosteroids and ACCUTANE. Therefore, caution should be exercised when using these drugs together.
Due to its lipophilic properties, absorption of ACCUTANE is increased when taken with food. Therefore, the recommended dose is to be taken with food (see DOSAGE AND ADMINISTRATION: Recommended Dose and Dosage Adjustment).
St. John’s Wort: ACCUTANE use is associated with depression in some patients (see WARNINGS AND PRECAUTIONS: Serious Warnings and Precautions, Psychiatric and ADVERSE REACTIONS: Psychiatric Disorders). Patients should be prospectively cautioned not to self -medicate with the herbal supplement St. John’s Wort because a possible interaction has been suggested with hormonal contraceptives based on reports of breakthrough bleeding on oral contraceptives shortly after starting St. John's Wort. Pregnancies have been reported by users of combined hormonal contraceptives who also used some form of St. John's Wort.
Dosage and Administration
The therapeutic response to ACCUTANE (isotretinoin) is dose-related and varies between patients. This necessitates individual adjustment of dosage according to the response of the condition and the patient’s tolerance of the drug. In most cases, complete or near -complete suppression of acne is achieved with a single 12 to 16 week course of therapy. If a second course of therapy is needed, it can be initiated eight or more weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug.
Recommended Dose and Dosage Adjustment
The initial dose of ACCUTANE should be individualized according to the patient’s weight and severity of the disease.
In general, patients initially should receive ACCUTANE 0.5 mg/kg body weight daily for a period of two to four weeks, when their responsiveness to the drug will usually be apparent. It should be noted that transient exacerbation of acne is occasionally seen during this initial period.
The daily dosage should be taken with food in the nearest number of whole capsules, either as a single dose or in two divided doses during the day, whichever is more convenient.
Maintenance dose should be adjusted between 0.1 and 1 mg/kg body weight daily and, in exceptional instances, up to 2 mg/kg body weight daily, depending upon individual patient response and tolerance to the drug.
A complete course of therapy consists of 12-16 weeks of ACCUTANE administration.
Patients may show additional improvement for up to several months after a course of ACCUTANE has been completed. With effective treatment, appearance of new lesions will not normally be evident for a period of at least three to six months.
|For the management of suspected drug overdose, please contact your regional poison control centre.|
In the event of acute ACCUTANE (isotretinoin) overdose evacuation of the stomach should be considered during the first few hours after this overdose. Signs and symptoms of acute overdose have been associated with headache, vomiting, facial flushing, cheilitis, abdominal pain, dizziness and ataxia. To date, all symptoms have quickly resolved without apparent residual effects and usually without treatment. Elevated intracranial pressure has been reported with patients receiving therapeutic doses of ACCUTANE. Patients with an ACCUTANE overdose should be monitored closely for signs of increased intracranial pressure. Signs of hypervitaminosis A could appear in cases of overdose.
Limited data exists on the pharmacokinetic characteristics of isotretinoin in an overdose situation. Following the oral administration of single 80, 160, 240 and 340 mg doses to 12 healthy male subjects Cmax was 366, 820, 1,056 and 981 ng/mL, and t1/2 was 13.6, 14.1, 14.4 and 16.5 hours for isotretinoin, respectively. Twenty-three compromised cancer patients received weekly oral doses of 200 (3 patients); 400 (7 patients); 660 (2 patients); 1,000 (3 patients); 1,400 (6 patients) and 1,800 (1 patient) mg/m2. Normal body surface area for healthy subjects is 1.73 m2. After the first dose, Cmax was 1.5, 3.8, 3.5, 2.5, 2.7 and 4.6 µg/mL, and t1/2 was 45, 9.1, 14.5, 57, 13.1 and 6.1 hours for isotretinoin, respectively. The absorption of isotretinoin appears to be a saturable process.
Since it is difficult to extrapolate from the results of these studies to the overdose situation, the following precautions should be taken with all female patients of childbearing potential who have taken an overdose of ACCUTANE.
- At the time of the overdose, a pregnancy test must be performed and a blood sample collected for the determination of isotretinoin and metabolite concentrations.
- One complete menstrual cycle after the overdose, a second pregnancy test must be performed and a second blood sample collected for the determination of isotretinoin and metabolite concentrations.
- Effective contraception must be used for at least one complete menstrual cycle after the overdose and continued longer, if necessary until physiological plasma concentrations of isotretinoin and its major metabolites are reached.
Patients who present with a positive pregnancy test at the time of the overdose, one complete menstrual cycle after the overdose, or while isotretinoin or metabolite blood concentrations are measurable, should be fully counselled on the serious risk to the fetus from this exposure to ACCUTANE and the physician and patient should discuss the desirability of continuing the pregnancy. (See CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, Special Populations, Pregnant Women and TOXICOLOGY: Reproduction and Teratology Studies).
Canadian Regional Poison Information Centres have been advised on the proper collection and handling of ACCUTANE blood samples and also on the laboratory(s) equipped to assay these samples.
Action and Clinical Pharmacology
Mechanism of Action
The mechanism of action of isotretinoin is unknown. Vitamin A is important for functional integrity of the skin and is known to affect the keratinization process. In acne patients, improvement occurs in association with a reduction in sebum secretion. The decrease in sebum secretion is temporary and is related to either the dose or duration of `ACCUTANE` administration and reflects a reduction in sebaceous gland size and an inhibition of sebaceous gland differentiation.
Following oral administration of 80 mg, peak plasma concentrations ranged from 167 to 459 ng/mL (mean 256 ng/mL) with a mean time to peak of 3.2 hours in volunteers, while in acne patients peak plasma concentrations ranged from 98 to 535 ng/mL (mean 262 ng/mL) with a mean time to peak of 2.9 hours.
When isotretinoin is taken with food, the bioavailability is doubled relative to fasting conditions (see DOSAGE AND ADMINISTRATION).
Isotretinoin is 99.9% protein bound in human plasma, almost exclusively to albumin.
The major metabolite identified in blood and urine was 4-oxo-isotretinoin. Tretinoin and 4-oxo-tretinoin were also observed. The apparent half-life for elimination of the 4-oxo-isotretinoin ranged from 11 to 50 hours, with a mean of 28 hours. Following 80 mg of isotretinoin administered orally, maximum plasma concentrations of the 4-oxo-isotretinoin was 87 to 399 ng/mL and maxima were observed between 6 and 20 hours. The blood concentration of the major metabolite generally exceeded that of isotretinoin after 6 hours. The data suggest that both isotretinoin and the major metabolite are excreted in the bile and reabsorbed.
The mean minimum steady-state blood concentrations of isotretinoin were 160 ng/mL in 10 patients receiving 40 mg twice daily doses. After single and multiple doses, the mean ratio of areas under the curves of 4-oxo-isotretinoin to isotretinoin was between 3 and 3.5.
The mean terminal elimination half-life of isotretinoin in patients with acne has a mean value of 19 hours. Following oral administration of 14C-isotretinoin, 14C activity in blood declined with a mean half-life of 90 hours. Approximately equal amounts of radioactivity were recovered in the urine and feces, with 65-83% of the dose recovered.
Special Populations and Conditions
The pharmacokinetics of isotretinoin were evaluated after single and multiple doses in 38 pediatric patients (12 to 15 years) and 19 adult patients (≥ 18 years) who received ACCUTANE for the treatment of severe recalcitrant nodular acne. In both age groups, 4-oxo-isotretinoin was the major metabolite; tretinoin and 4-oxo-tretinoin were also observed. The dose-normalized pharmacokinetic parameters for isotretinoin following single and multiple doses are summarized in Table 1 for pediatric patients. There were no statistically significant differences in the pharmacokinetics of isotretinoin between pediatric and adult patients.
|Cmax (ng/mL)||573.25 (278.79)||731.98 (361.86)|
|AUC(0-12) (ng hr/mL)||3033.37(1394.17)||5082.00 (2184.23)|
|AUC(0-24) (ng hr/mL)||6003.81 (2885.67)||–|
|Tmax (hr)†||6.00 (1.00-24.60)||4.00 (0-12.00)|
|Cssmin (ng/mL)||–||352.32 (184.44)|
|CL/F (L/hr)||–||17.96 (6.27)|
*The single and multiple dose data in this table were obtained following a non-standardized meal (non-high-fat meal).
† Median (range)
In pediatric patients (12 to 15 years), the mean SD elimination half-lives (t1/2) of
isotretinoin and 4-oxo-isotretinoin were 15.7 5.1 hours and 23.1 5.7 hours, respectively. The accumulation ratios of isotretinoin ranged from 0.46 to 3.65 for pediatric patients.
Storage and Stability
ACCUTANE (isotretinoin) 10 mg and 40 mg capsules: Store at 15-30◦C. Store in the original package. Protect from exposure to moisture, heat and light.
Keep in a safe place out of the reach of children.
Special Handling Instructions
The release of pharmaceuticals in the environment should be minimized. Medicines should not be disposed of via wastewater and disposal through household waste should be avoided. Use established “collection systems” if available in your location.
Return any unused ACCUTANE (isotretinoin) capsules to the pharmacist.
Dosage Forms, Composition and Packaging
|10 mg capsules:||Brown-red opaque, oval-shaped soft gelatin capsules containing
10 mg isotretinoin, imprinted ❛ROA 10❜.
|Non-medicinal ingredients (alphabetical order): beeswax, black
iron oxide, gelatin, glycerol, hydrogenated hydrolysed starch,
hydrogenated soybean oil, mannitol, partially hydrogenated
soybean oil, propylene glycol, red iron oxide, shellac, sorbitol,
soybean oil, titanium dioxide.
|40 mg capsules:||Yellow opaque, oval-shaped soft gelatin capsules containing
40 mg isotretinoin, imprinted ❛ROA 40❜.
|Non-medicinal ingredients (alphabetical order): beeswax, black
iron oxide, gelatin, glycerol, hydrogenated soybean oil,
methylparaben, partially hydrogenated soybean oil, propylene
glycol, propylparaben, quinoline yellow WS, shellac, soybean oil,
sunset yellow FCF, titanium dioxide.
ACCUTANE 10 mg and 40 mg capsules are available in blister packages of 30 capsules.